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Cardiovascular disease (CVD) is currently the leading cause of death in U.S. women.  As 
of 2011, CVD events account for 52.8% of among this population (Heart Disease and Stroke, 
2012).  A greater portion of women die from cardiac death related to CVD prior to arrival to the 
hospital (52%) then men (42%) (Shaw, 2009).  Cardiac related deaths in women still remain one 
of foremost public health concerns.  These statistics in the female population have remained 
consistently high while those of male counterparts are shown to be decreasing (Shaw, 2009). 
According to major U.S. healthcare organizations such as the American Heart 
Association (AHA), the Center for Disease Control (CDC), and the World Health Organization 
(WHO), CVD is considered to be the number one healthcare topic of healthcare related 
concern these days. CVD encompasses multiple symptoms and disease processes contributing to 
debilitating morbidities and fatal outcomes.  Including of, but not limited to, coronary heart 
disease, hypertension, congestive heart failure, and stroke.   Another concern emerging is the 
consequences of cardiovascular disease in the female population.  
 Commonly considered by most to be a disease process characterized by male prevalence 
with stereotypical symptoms, there are many varying factors concerning women and CVD.  
These factors are evolving trends and could guide decisions of healthcare providers in treating 
female patients as a separate entity.  Thus promoting the most health merited benefits of therapy 
and treating existing disease effectively.  Females exhibit difference in vasculature structure, 
endocrine changes, and responsiveness to medications that adversely affect structure and 
integrity of a finely balanced circulatory system, when compared to their male counterparts.  
Shared risk factors and these variances for men and women could potentate these risk factors and 
lead to higher threats of morbidity and morality among the female population. These combined 
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factors in conjunction with atypical symptom presentation often lead to misdiagnosis and under 
treatment, permitting CVD to remain the leading cause of death in women. 
Cardiovascular Disease in Women: The Differences in Genders 
 Cardiovascular disease is an umbrella term used to encompass many diseases of the 
vascular system.  Including, but not limited to, coronary artery disease, myocardial infarction, 
stroke, and hypertension.  Top healthcare organizations such as WHO, CDC, and AHA consider 
these disease processes to be the number one health disparity and cause of mortality in today’s 
society overall as well as specifically in women.  These diseases are also a heavy financial pull 
on the healthcare system with the resulting treatment, rehabilitation and missed wages.  Based on 
statistics from the AHA in 2009, CVD accounted for 236.1 per 100,000 deaths.  That breaks 
down to a rate of 2150 deaths per day from CVD; or one death every 40 seconds (Statistical Fact 
Sheet Update, 2013).  When evaluating heart disease specifically, it is still determined by the 
healthcare community, to be the number one killer in both men and women (Heart Disease Fact 
Sheet, 2012).  CDC 2009 statistics, heart disease accounts for approximately 600,000 deaths 
annually, that is one death every minute from heart disease (Heart Disease Fact Sheet, 2012).  
The National Conference of State Legislatures attests that treatment for cardiovascular diseases 
accounts for nearly $1 of every $6 spent on health care in the United States. In 2010, an 
estimated $444 billion was spent on CVD, treatment, medication and lost productivity from 
disability.  
In reviewing the impact CVD has on the female population, the mortality rates are much 
higher in females. Even though a higher percentage of males suffer from CVD insults, the 
mortality rates are higher in the female population from the effects (Shaw, 2009).  One in three 
females has some form of cardiovascular disease (AHA, 2013).  CVD has claimed the lives of 
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401,495 women in 2009.  Compare this to 270,865 deaths caused by all combined cancers, 
making CVD accountable for 51% of deaths of this cohort (Statistical Fact Sheet, 2013).  
The Women’s Ischemia Syndrome Evaluation (WISE) study sponsored by the National 
Institute of Health (NIH) made significant discoveries in gender specific differences.  These 
differences include; the pathophysiology of CVD processes, anatomy involved in this disease 
process and responses to therapies provided for the prevention and treatment of CVD and 
presenting symptoms (Finks, 2010).  These differences can lead to significant consequences from 
failure to acknowledge the variances and treat accordingly. 
The question addressed through this literature review is; if there is a measurable decrease 
in the number of deaths overall from CVD, leading to the belief that there are effective 
screening, identification and treatment of risk factors, why is there not a same measurable 
reduction in the number of women as an identifiable population suffering from CVD and heart 
disease (HD)?  
Can men and women demonstrating risk factors or current disease processes of CVD be 
grouped together in the same assessment and treatment category, or are there definitive 
differences in the populations which would warrant distinguished assessment and treatment 
algorithms based on gender.  In addition, are the commonly used treatment options beneficial to 
women who are at an increased risk of mortality and morbidity, and can this confirmed by 
current statistical research? 
The purpose of this literature review is to: evaluate the current screening methods used to 
identify risks for CVD, and determine the effectiveness of therapy commonly prescribed in 
treatment of as women with this disease(s).  Thus enabling providers to better manage these 
women at risk for CVD and prevent further progression into a higher risk category.  Outcomes of 
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better therapy, including primary, secondary, and tertiary therapy, show effective measurable 
results of reducing incidence of CVD in women. 
The framework used to guide this study was the Neuman’s systems model.  In preventing 
CVD in women, the three levels of prevention should be used to guide providers in optimal CVD 
therapy benefits.  Primary prevention is determining a woman’s potential for risk factors and 
promoting education on prevention of these risks.  Secondary prevention would be effective 
screening and treatment of current risk factors and current disease processes in order to avoid 
progressing into a high level of risk.  Tertiary prevention includes treatment of morbidities 
resulting from a CVD effect, and prevention of complications of further disease progression. 
Within the Neuman’s model there are variables which must be incorporated into 
treatment and prevention in women.  These include; the physiological structure and function of 
the body, the mental processes and relationships, the sociocultural and spiritual variables, and 
overall development.  There are also known and measurable stressors as well as unknown and 
unforeseen stressors which can disrupt or change a balance in the variables, altering the 
effectiveness of outcomes of research or treatment therapy.  All these play a role in deciding 
effective preventative measures, assessment techniques and treatment options.  
In conducting this literature review, criteria in searching for articles included the phrases; 
women and cardiovascular disease, women and heart disease, heart disease and gender 
differences and cardiovascular disease.  Articles were then chosen based on relevance to the 
topic of cardiovascular disease, inclusion of gender analysis and a patient population of more 
than 100 participants. No articles older than 2002 were included in this review in efforts to keep 
with the more up to date and accurate research within the previous 10 years.  Statistical data 
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incorporated into this review was retrieved from credible healthcare organizations, including the 
CDC, WHO and AHA, from the year 2009 to present. 
In shaping the underlying foundation in dissimilarity of the pathophysiology, 
presentation, risks for, and treatment of CVD in women, defining the potentials of these 
variations is vital.  Once the root, or roots, for variation is discovered and established, it is 
necessary to evaluate treatment options commonly used.  Then decide their benefit verses 
vulnerability in treating the female population at risk for or recovering from CVD.  A secondary 
goal of this review is to raise awareness in providers to educate their women patients on their 
risk factors, both modifiable and non-modifiable, for CVD as well as the consequences of this 
disease and available optimal treatment methods. 
Mosca, Manson, Sutherland, Langer, Manolio, et al, (2009), found that through education 
and raising awareness of the risk of CVD to women, there was a heightened awareness of 
individual risk and a sense of ownership of protecting one’s health from those risk factors.  The 
Heart Truth campaign initiated in 2001 is sponsored in the United States by the National Heart, 
Lung, and Blood Institute, more commonly known as the “Red Dress” campaign, which was 
designed to help raise public awareness of the risks of CVD knowledge and awareness of leading 
cause of death among women.  This campaign hoped to lead an increase in public education and 
also evaluate the current public knowledge regarding CVD.  Efforts of this campaign continue 
today, gaining popularity and raising awareness of the health disparities of CVD.  Presently 55% 
of surveyed participants correctly identified heart disease as the leading cause of death compared 
to 30% in 1997 (Mosca et al., 2009).  Before this public campaign effort there was a lack of 
discrepancy between the risk of men and that of women as CVD which was considered by the 
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public as a male population disease, and was studied and treated according to outcomes within 
this male population based research. 
Oliver-McNeil and Artinian (2009) demonstrated that 93% of surveyed participants, 
although knew they had some risk for CVD, were not aware of their individual risk and what 
they could do to lower their risk of potentially suffering the effects of CVD.  Worrall-Carter, Ski, 
Scruth, Cambell, & Page (2011) found that in the female population, most risk factors are 
modifiable and are simply overlooked or underestimated by providers and public alike. 
According to their study, women are often underrepresented in trials in identifying and treating 
risk factors. The highest risk factors associated with CVD in women were diabetes mellitus, 
smoking, and hypertriglyceridemia, (Worrall-Carter et al, 2011). These risks are all modifiable or 
preventable, meaning they are improvable and in turn, if treated appropriately, could lower the 
risk of a future CVD event (Worrall-Carter et al, 2011).  However Mosca et al, (2009) found that 
more often than not, women were deemed by providers to be at low risk for CVD, therefor were 
under identified for these risk factors and not treated effectively to prevent further progression of 
CVD. 
 There was a lack of determining women with potential of developing CVD by healthcare 
providers, despite demonstrating the same risk factors listed as culprits by standardized national 
healthcare organizations.  Physician awareness of three national CVD prevention guidelines 
(NCEP ATP III, JNC 7 and AHA) differed by specialty of practice; Family Practice, Obstetrics 
and Gynecology, and Cardiology.  The rate of highest identification of potential CVD disease in 
the patient population was that of cardiologists (80%) although it was still not comparable to the 
rate of identification of CVD in the male population by cardiologists (95%).  Rates of 
recognition lowest among OBGYN (58%), although their specialty is caring for the female 
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population, including women suffering with high risk cardiovascular processes such as eclampsia 
and pregnancy induced cardiomyopathy. Physician incorporation of therapy guidelines for 
women were again highest among cardiologists (59%) followed closely by PCPs (46%).  The 
least likely to employ the guidelines for therapy were OBGYN physicians who specifically 
treated women (24%) (Mosca, Linfante, Benjamin, Berra, Hayes, et al., 2005). 
In reviewing the pathophysiological differences of women in reference to CVD, Shaw 
(2009) determined women to have less anatomical and obstructive coronary disease (<50% of 
women with symptoms of cardiac disease), but found to have higher rates of ischemic disease, 
with a relatively preserved left ventricular function. This study also found this to contribute to 
women having an increased overall CVD mortality compared to similarly aged males.  “The 
WISE study implicates abnormal coronary reactivity, microvascular dysfunction and plaque 
erosion with distal microembolization as female specific ischemic heart disease 
pathophysiology” (Shaw, 2009)  
More than half of these women undergo repeated hospitalizations with signs and 
symptoms of heart ischemia without objective findings such as coronary artery disease.  Thus 
leading Shaw (2009) to determine heart disease prevalence in women to be predominately 
ischemic heart disease (IHD) (Shaw, 2009).  These findings limit conventional treatment 
measures, such as cardiac catherization or coronary bypass grafting from preventing the 
occurrence of mortality and morbidity from heart disease such as myocardial infarction, direct 
cardiac hypoxia, or atherosclerotic disease.  A study of female sex as an independent predictor of 
survival and morbidity was conducted by Ahmed, Tully, Knight, and Baker (2011) who included 
a gender differential of their results from a study of 4,742 participants (23% of which were 
female) with a 7.9 year median follow up from receiving coronary artery bypass grafting 
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(CABG). The authors discovered that the women who suffered cardiac injury, despite receiving 
CABG, were associated with early morbidity and long-term cardiac mortality. They also note 
that more female participants were older in age, carried higher numbers of concomitant 
morbidities. Prior to undergoing coronary artery bypass grafting were already with greater 
proportion of cardiac risk factors once patients were identified to be in need for bypass grafting 
(Ahmed, et al., 2011). 
Grines (2012) discussed the outcomes of women who presented for cardiac 
catheterzation, verse men in cardiac catheterizations with stent placement, and were older and 
with more comorbidities then men. Women were also at a higher risk for mortality after cardiac 
catheterization which was not consistently eliminated after adjustments for comorbidities.  
Women were also found to be at a higher risk for bleeding, incomplete revascularization and 
failure to deploy stent second to smaller coronary arteries (Grines, 2012). 
 So this raises the question; are there are specific female risk factors for CVD related to 
the circumstance of being of the XX gene as opposed to the XY gene or is it simply a matter of 
under education and treatment initiation by providers to a population at risk as the previous 
studies listed have demonstrated that leads to this health care crisis? 
 In reviewing some female specific issues concerning CVD, Miller & Best (2009) states 
that “the lack of attention to sex differences in etiology of cardiovascular disease has resulted in 
inadequate methodologies and strategies to prevent, diagnose, and treat cardiovascular disease in 
women compared to that in men.”  In reviewing sex disparities in associated risks of CVD, the 
authors review three categories of risks; conditions unique to one sex such as menopause and 
pregnancy induced hypertension in women, conditions which can occur in both sexes, and 
conditions that are occurring to both sexes but present differently per gender.  Through their 
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research presentation, the authors emphasize the importance in the need for the developing a 
valid assessment tool for use, which will incorporate information regarding not only the risk 
factors found in both genders, but with given attention to reproductive history including hormone 
therapy, menopause, pregnancy exposure and complications or risks within the reproductive 
years which may contribute to a increased risk of developing CVD. 
There has been a great deal of controversy over the role played by hormone therapy in 
relation to the progression of risk in CVD events and whether or not estrogen therapy is indeed 
beneficial in preventing these events. Or whether the risks associated with the therapy outweigh 
what benefit there may be.  Miller (2010) found that sex steroids affect all components of the 
vascular wall, heart, as well as blood elements which come in contact with luminal surfaces of 
the vascular system. Once these hormonal levels are altered, the vasculature system becomes 
vulnerable to adverse effects of this change.  This includes but not limited to poor vascular 
contractibility which can result in consistently constricted vessels, or thinning of luminal wall 
making the vessel exposed to damage.  Estrogen was noted to carry a high role in the vascular 
dilation in premenopausal women by endothelium-dependent vascular relaxation through nitric 
oxide (NO), prostacyclin, and hyperpolarization pathways (Orshal & Kahlil, 2013).  However, 
clinical trials such as the Heart and Estrogen/Progestin Replacement Study (HERS), HERS-II, 
and the Women's Health Initiative did not support the experimental findings and instead 
demonstrated adverse cardiovascular events of hormone therapy (HT) in aging women such as 
vascular embolization and heart failure.  The lack of vascular benefits of HT may be related to 
the hormone used, the estrogen replacement, or the patient's particular cardiovascular condition 
or age (Qiao, McConall & Kahlil, 2008).  These studies suggest not necessarily the need for 
HRT in order for vascular protection, but early identification and proper treatment in regards to 
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hypertension is the most beneficial form of CVD prevention and therapy for postmenopausal and 
premenopausal female patients. 
Another area found to be at specific increased risk for the female patient was 
hypertriglyceridemia and diabetes mellitus.  A Canadian led global INTERHEART standardized 
case-control study was conducted that measured the nine greatest risk factors for CVD. This 
study screened all patients admitted to the coronary care unit or equivalent cardiology ward for a 
first MI at 262 participating centers in 52 countries.  Through this study it was determined that 
hypertriglyceridemia was an independent risk factor in determining a female risk for heart 
disease (O’Riordan, 2004).  Diabetes mellitus (DM) was identified as having the greatest 
difference for developing CVD, placing women with DM at a 3-4 fold increase of developing 
CVD in comparison to women without DM (Worrall-Carter, et al., 2011).  Matthews, Crawford, 
Chae, Everson-Rose, Sowers, et al. (2009) also concluded through their study that there was a 
measurable substantial increase in total cholesterol and low density lipoprotein (LDL) at the time 
of final menstrual period (FMP).  Although the relationship between estrogen and lipid 
regulation is not completely understood, it stands to hypothesize that physiologic levels of 
estrogen are known to help maintain favorable lipoprotein profiles in women.  Once a women 
enters menopause and the levels of estrogen rapidly declining, levels of high density lipoprotein 
(HDL)-cholesterol decrease while triglyceride levels and well as LDL- cholesterol levels begin 
to rise.  A low HDL-cholesterol level is a strong forecaster of increased risk of CVD in women. 
The average HDL cholesterol level in moderately healthy adult women is 55 to 60 mg/dL.  A 
decrease in HDL cholesterol level of 10 mg/dL increases overall coronary disease risk by an 
estimated 40 to 50 percent.  
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When evaluating treatment through pharmacological therapy for women, it was noted 
there was several treatment algorithms in which women either benefited or did not benefit in 
therapy at all in comparison to men or the average measured statistics.  Walsh and Pigone, (2010) 
reviewed the most common medical management and the difference in effects on patients in 
regards to gender. In men there was a definite reduction of CVD events with preventative 
pharmacological therapy, regardless of the deemed level of risk.  In women being treated with 
the same preventative pharmacological therapy, there was only a minimal reduction of risk 
within categories of women deemed to be a moderate to higher risk of CVD. An individual level 
of risk is determined by presence of current risk factors. This includes current presence of both 
modifiable and non-modifiable such as genetics, treatment and compliance with the treatment 
goals, as well as current presence of disease which exacerbates CVD such as hypertension, 
hyperlipidemia and diabetes.  These factors are all used to assess and determine a person’s risk 
for developing or experiencing a CVD occurrence when considering initiation of 
pharmacological therapy. 
 Lipid lowing pharmacological therapy initiated in women patients with hyperlipidemia, 
defined as an increased level of serum cholesterol and triglycerides, was found to reduce 
incidence of CHD by 50% (Mosca, et al., 2009).  Use of these agents in women without a 
demonstrated case of CVD, although a reduction in CHD events was determined, there was not a 
proven reduction in overall CVD mortality.  In women with known CVD, use of anti-
hyperlipidemia medications found a decrease in more CHD events and associated mortality 
(Walsh & Pigone, 2004). 
In evaluating antithrombotic therapy, women were found to be at a disadvantage with the 
pharmacological treatment.  Aspirin therapy affects women differently than men as deduced 
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through a study by Xhyheri & Buliardini (2010), finding that aspirin is more effective in 
preventing a MI in men (32%), but decreased stroke risk in women (17%).  Plavix was found to 
be less effective in reducing the risk of a CVD event in women (7%) then men (16%) while 
therapy was associated with an increased risk of bleeding in women (43%) then men (22%). 
Hypertensive therapy is also complicated in women as earlier discussed by the loss of sex 
steroids in post-menopausal women, reducing the vasodilation response of the vascular system. 
Traditional treatment options studied by Xhyheri & Bulgiardini (2010), which were used for post 
therapy after a cardiovascular event, was determined to have a different effect on women.  ACE 
inhibitors used in post recovery from MI or CHF events was shown to have less effectiveness in 
women (22%) then men (37%).  Beta blockers were found to be more effective in women (31%) 
then in men (5%). 
 Through the research conducted for this review, it was noted that multiple articles either 
cited or demonstrated the lack of female participants within the current research regarding the 
study of risks of developing CVD, as well as the treatment, and consequences of CVD.  Many 
reasons for this lack of inclusion were listed including, risk of injuring a fetus by including 
women of child bearing age, altering fertility abilities, variability in data results by incorporating 
women undergoing hormone therapy, or lack of participants by failing to recognize pertinent risk 
factors or symptoms for research inclusion.  Worrall-Carter cited that not only women were 
underrepresented in CVD prevention and treatment trials (30%) nut were not represented 
properly as most women included were statistically older with more comorbidities then the male 
counterparts.  There was also a under representation of gender differences in research studies. 
Only one-third of studies evaluated cited these gender specific findings.  This leads most 
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outcome based treatment theories being predominately geared towards a male population 
(Worrall-Carter, et al., 2011). 
 The Framingham study is considered a landmark research study, as it incorporates the 
female population individually as well as gives particular details to the risk assessment, treatment 
and trending details about cardiovascular disease in women.  According the Framingham 
website, they state: 
“Since our beginning in 1948, the Framingham Heart Study, under the direction of the 
National Heart, Lung and Blood Institute (NHLBI), formerly known as the National 
Heart Institute, has been committed to identifying the common factors or characteristics 
that contribute to cardiovascular disease (CVD). We have followed CVD development 
over a long period of time in three generations of participants.” 
(Framinghamheartstudy.org). 
 This study is currently ongoing, presently in the fourth generation of study, and focuses 
on using the data collected to the development, progression, and effects of treatment of 
cardiovascular disease.  Over the years, careful monitoring of the Framingham Study population 
has led to the identification of major CVD risk factors.  This study contributes valuable 
information on the effects of these risk factors, such as blood pressure, blood triglyceride and 
cholesterol levels, age, gender, and psychosocial issues in the development of CVD in women.  
This landmark research raised awareness to there being a prevalent gender difference in regards 
to CVD.  Risk factors for other physiological conditions in women, such as dementia, have been 
and continue to be investigated. In addition, the relationships between physical traits and genetic 
patterns predisposing women the CVD processes are continued to be studied 
(Framinghamheartstudy.org).  
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 In exploring the literature in this study, there is a definite difference in the process of 
identifying CVD in women and ideal treatment therapy.  The research determined not only is 
there a lack of identification by providers of women presenting with risk factors, there is 
suboptimal therapy initiated if any therapy prescribed at all.  This deficiency of healthcare to a 
population at risk is contributing to a failure in declining the statistics of morbidity and mortality 
of women, as well as using a great deal of healthcare dollars on highly preventable disease.  In 
treatment of the disease process encompassed in CVD, there is a need for a sex based screening 
and gender based treatment algorithm for providers.  
Increasing public awareness of this issue would raise knowledge of risk factors to those 
demonstrating these threats which in turn would possible, prompt further cessation of risk. 
Promoting behavior through a sense of health conscious ownership as well as encouraging 
women to discuss concerns with their healthcare providers.  
The limitations of this study are the lack of substantial gender based data.  There is a 
consistent acknowledgement of a lack of women participants or gender distinction in studies or 
reviews conducted.  Even with the inclusions of the available data for gender discernment in 
these trials, there was a definite greater participation of men which leads to question the validity 
of the results from these trials.  The Framingham study which was created in effort to include 
women and gender differences over a period of generations acknowledges the lack of female 
participants.  There needs to be more focused research on the adequate treatment of CVD as it 
pertains to female population well as reducing the risk of developing high risk probability of an 
event and providing pertinent education to the patients in reducing their risk.  Development of a 
gender based assessment and treatment algorithm.  If available to providers, it would be 
beneficial in identifying a women’s tendency to developing CVD as well as prime treatment 
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therapy to decrease her risk of suffering the effects of this disease process.  This in turn could aid 
in decreasing the devastating statistics currently plaguing the women of America today. 
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Appendix Design and Purpose Population (N) Intervention/Interpre
tation 
Findings 
Oliver-McNeil, S., Artinian, 
N. & Beaumont, W. (2002). 
Women’s Perceptions of 
Personal Cardiovascular Risk 
and Their Risk-Reducing 
Behaviors. American Journal 
of Critical Care, 11, 221-227. 
Descriptive study 
conducted at a 925-bed 
teaching hospital to 
describe perceptions of 
cardiovascular risk factors 
and risk-reducing 
behaviors among women 
patients newly diagnosed 
with cardiovascular 
disease. 
33 women > 18 
years or older with 
CAD diagnosed with 
angiographic 
findings or 
confirmation of a MI 
within the preceding 
7 days 
 
Mentally competent 
as evidences by 
living independently 
in the community, 
no prior history o 
Cad and able to read 
and write english 
SPSS descriptive 
statistics were used to 
analyze all study 
variables and the 
research questions. 
This study concluded that 
women included had limited 
awareness of their personal 
risk limiting their ability to 
participate in CHD 
prevention 
 
Documented risk factor in 
medical records did not 
correlate with patients 
perceived risks, however did 
correlate with the AHA 
cardiovascular risk factors 
excluding  body mass index 
and life stress 
 
Despite 93% of participants 
knew they had some risk for 
CAD, they were unaware 
they had multiple risk 
factors or the impact these 
risks held for their overall 
health 
 
There was no identified 
relationship between risk 
identification and risk-
reducing behaviors. 
Mosca, L., Mochari, H., 
Christian, A., Berra, K., 
Taubert, K., Mills, T., et al. 
(2006). National Study of 
Women’s Awareness, 
Preventive Action, and 
Barriers to Cardiovascular 
Health. Circulation, 113, 525-
534. 
A meta-analysis study 
conducted through surveys 
to determine the current 
knowledge of 
cardiovascular disease in 
public women. 
1485 women >25 
years of age 
completed the 
survey.  
 
A total of 18905 
calls were made to 
include the number 
of volunteer 
participants. 
.Statistical analysis of 
the data was completed 
using SPSS. 
 
Logistic regression 
models were used to 
determine knowledge 
of variables. 
 
X2 analysis was used 
to determine the 
association of 
perceived risk and 
defined risk.  
 55% correctly identified 
CVD as the leading cause of 
death compared with 30% in 
1997 (P<0.05) 63.1% of 
cited CVD as the leading 
cause of death in men. 
 
Awareness among women 
who considered themselves 
at an increased risk 
(moderate or high) was 
higher then women who 
perceived themselves to be 
at a lower risk (59.4% vs 
60.9% vs 49.0%) 
 
81% of women said they had 
heard or read about the 
prevalence of heart disease 
in the past 12 months. These 
women were more likely to 
be aware of CVD as the 
leading cause of death in 
women (68.9% vs 51.2%; 
P<0.0001) 
 
88% confirmed they had 
yearly checkups with their 
healthcare provider. 54% 
said their healthcare provider 
discussed their risk factors 
for CVD. 
 
Overall statistics showed the 
women who were more 
aware of the risks for CVD 
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deemed themselves at a 
moderate to high risk level. 
These women were more 
proactive in decreasing their 
risk factors then those 
women who considered 
themselves at low risk.  
Weiss, A. (2009). 
Cardiovascular Disease in 
Women. Primary Care Clinic 
Office, 36, 73-102. 
 
This descriptive study was 
conducted to discern the 
gender specific differences 
in the physiology, 
presentation of symptoms’ 
and treatment of 
cardiovascular disease 
  CVD affects women 
disproportionately then it 
does men as it is diagnosed 
less frequently, treated less 
effectively, and carries a 
higher mortality rate in 
women. Today CVD affects 
42.1 million women (36.6% 
of the female population) 
and accounts for 41.3% of 
all deaths of American 
women. 
 
The cost of healthcare for 
CVD in 2005 was projected 
at $394 billion: $242 billion 
in direct healthcare costs and 
$152 billion in lost 
production and wages. 
 
The lifetime risk for CVD in 
2 in 3 for men and 1 in 2 for 
women. Annual rates of first 
major CVD event for 
women track those of men 
but are delayed by 10 years. 
 
In persons younger the 75 
years of age, more CVD 
events occur in men because 
of CHD than women, 
whereas more CHF events 
occur in women than men. 
 
There are less “common” 
presentation symptoms of 
CVD/CAD in women than 
in men which often lead to a 
misdiagnosis.  
 
The lifetime risk of dying 
from a stroke is twice that of 
men (16% vs 8%) 
 
Two thirds of sudden deaths 
in women occurred in 
women without and history 
of symptoms whereas only 
50% of men were similarly 
affected. 
 
Women have a higher 
incidence of death in the first 
year after a heart attack then 
men (38% compared to 
25%), twice as likely as men 
to die after bypass surgery, a 
higher rates of disability due 
to heart failure within 6 
years after a MI (46% to 
22%) 
Vaid, I., Wigington, C., 
Borbely, D., Ferry, P. & 
This open cohort study 
design assesses and 
WISEWOMAN 
began in 1993 to 
The current (4th) phase 
of WISEWOMAN 
Women with low income 
endure a disproportionate 
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Manheim, D. (2011). 
WISEWOMAN: Addressing 
the Needs of Women at High 
Risk for Cardiovascular 
Disease. Journal of Women’s 
Health, 20(7); 977-982. 
 
discusses the finding of the 
WISEWOMAN study 
program. 
extend preventative 
health services 
offered to women 
who participated in 
the National Breast 
and Cervical Cancer 
Early Detection 
Program 
(NBCCEDP). 
supports grantees in 
developing partnerships 
that will bring about 
policy, environment, 
and system changes in 
efforts to support heart 
healthy behaviors. 
impact of the burden of 
CVD resulting from limited 
access to healthcare resulting 
from being uninsured or 
limited financial means. 
Wenger, N. (2012). Women 
and Coronary Heart Disease: 
A Century After 
Harrick:Understudied, 
Underdiagnosed and 
Undertreated. Circulation, 
126, 604-611. 
 
A primary study of 
descriptive design to 
discuss the current status 
of studies of CHD in 
women from 1992-2012 
including the challenges 
met with these studies and 
the proposed treatment 
outcomes hypothesized. 
  Lack of public awareness of 
CHD in women in risk 
determination, symptom 
presentation, screening 
techniques, diagnostic 
procedures, and sex 
disparities in application of 
evidence based therapies 
contribute to poor CHD 
outcomes. 
 
Despite CVD burden, 
women remain 
unrepresented in clinical and 
are at a disadvantage by 
absence of sex –specific 
analysis. 
Mosca, L., Linfante, A., 
Benjamin, E., Berra, K., 
Hayes, S., Walsh, B., et al. 
(2005). National Study of 
Physician Awareness and 
Adherence to Cardiovascular 
Disease Prevention 
Guidelines. Circulation, 111, 
499-510. 
 
Online cross-sectional 
survey including case 
studies to assess 
knowledge of screening, 
preventative and 
interceptive therapies and 
tools 
500 randomly 
selected physicians 
(300 primary care, 
100 OB/GYN, 100 
cardiologists) drawn 
from the J. Reckner 
Associated database 
Descriptive statistics of 
physician practices and 
preventative 
recommendations were 
presented as 
proportions 
 
Physician awareness of 3 
national CVD prevention 
guidelines (NCEP ATP III, 
JNC 7 and AHA) differed by 
specialty of practice  
 
Physician recommendations 
about lifestyle interventions, 
supplements, and aspirin 
therapy were sub optimal 
among low-risk patients 
across the specialties 
 
Supplements were more 
highly recommended among 
the mid to high risk 
populations 
 
Results for correctly 
identifying risks for patient 
populations considering 
gender difference were 
similar across the specialties. 
Women risks were identified 
less often than that of males. 
Women were also more 
likely to be assigned to a low 
risk category despite being  a 
similar calculated risk as 
men 
Mochari-Greenberger, H., 
Mills, T., Simpson, S. & 
Mosca, L. (2010). 
Knowledge, Preventive 
Action, Barriers to 
Cardiovascular Disease 
Prevention by Race and 
Ethnicity in Women; An 
American Heart Association 
National Survey. Journal of 
Women’s Health, 19(7): 1243-
1249. 
 
Survey using standardized 
questionnaire about 
knowledge of healthy risk 
factor levels, preventative 
actions and barriers to 
preventative actions. 
 
The purpose of this study 
was to assess differences in 
CVD knowledge, 
preventative actions, and 
barriers to prevention by 
racial/ethical group in a 
nationally representative 
1008 women >25 
years of age with at 
least one person 
living in their 
household or one 
person not living in 
their household for 
whom they made 
healthcare decisions 
for 
Descriptive statistics of 
respondents’ 
characteristics, 
knowledge level, 
preventative actions 
and barriers to these 
actions were evaluated 
between the ethnic 
groups. 
Knowledge that CHD is the 
leading cause of death varied 
by racial/ethnic groups 
which were independent of 
age, marital status, 
education, employment, 
income level or having 
children 
 
Hispanic populations was 
more likely to be unaware of 
the correlation between 
blood pressure and CVD 
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sample of women. Blacks and Hispanics were 
less likely than 
Caucasian/other groups to be 
aware that lipid levels  were 
in correlation with the risk of 
CVD 
 
Race/ethnicity was not 
associated with the risk of 
increased fasting blood 
glucose levels in relation to 
CVD, although those 
respondents with <4 years of 
college education were 25% 
less likely to know optimal 
fasting blood glucose level 
Heidenreich, P., Trogdon, J., 
Khavjou, O., Butler, J., 
Dracup, K., Ezekowitz, M., et 
al. (2011). Forecasting the 
Future of Cardiovascular 
Disease in the United States: 
A Policy Statement From the 
American Heart Association. 
Circulation, 123, 933-944. 
 
A case study using 
primary, secondary studies 
randomized and controlled 
studies to forecast the 
future costs and national 
effects needs for treating 
cardiovascular disease 
from the year 2010 – 2030. 
  CVD is responsible for 17% 
of national health care 
expenditures and expected to 
increase as the population 
ages. 
 
By 2030 – 40.5% of the US 
population is predicted to 
have some form of CVD. 
 
People >65 years of age is 
determined to have a higher 
prevalence of CVD, and this 
population segment is 
expected to grow 
significantly over the next 
two decades. 
 
Between the years of 2010-
2030, projected healthcare 
costs for treating CVD is 
forecasted to triple from 
$273 billion/year to $818 
billion/year. 
 
Indirect costs such as lost 
wages due to CVD disease is 
projected to increase by 61% 
(from $172 billion in 2010 to 
$276 billion in 2030.  
Shaw, L., Bugiardini, R. & 
Merz, N. (2009). Women and 
Ischemic Heart Disease. 
Journal of the American 
College of Cardiology, 
54(17): 1561-1575. 
 
This study was a cross-
sectional design conducted 
to evaluate the authors 
given hypothesis that 
women experience more 
adverse outcomes 
compared with men in the 
treatment of CAD because 
obstructive CAD remains 
the current focus of 
therapeutic strategies. 
  Cardiac death remains the 
leading cause of death in 
women of all ages. 
 
Women have less anatomical 
obstructive CAD yet greater 
rates of myocardial ischemia 
and mortality compared with 
similarly aged males. 
 
Contributing factors to 
higher female ischemic 
cardiac rates include 
abnormal coronary 
reactivity, 
microvascularization 
dysfunction, and plaque 
erosion, and distal 
microembolization . 
 
A greater proportion of 
women die from sudden 
cardiac death prior to arrival 
at the hospital (52% 
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compared with 42% of men). 
 
More than 80% of midlife 
women have 1 or more 
traditional cardiac risk 
factors.  
 
Over half of symptomatic 
women without obstructive 
CAD continue to have 
symptoms and undergo 
multiple hospitalizations and 
testing which result in 
diagnostic and therapeutic 
uncertainty. 
Gleeson, D. & Crabbe, D. 
(2009). Emerging Concepts in 
Cardiovascular Disease Risk 
Assessment: Where do 
Women Fit In? American 
Academy of Nurse 
Practitioners, 21, 480-487. 
 
The purpose of this review 
of literature was to 
determine and highlight the 
limitations in the 
assessment of women and 
discuss the current 
information in the process 
of assessment of risk 
factors in the female 
patient population, the 
pitfalls of these processes 
and the role these risk 
factors play in CVD. 
  Use of oral contraceptives in 
conjunction with smoking is 
associated with a significant 
risk of developing 
thrombosis and CVD 
complications.  
 
The mortality among males 
with diabetes is twofold 
higher, and fourfold higher 
than the general population 
for CV illness. 
 
Women have a one in six 
chance of developing heart 
failure from hypertension 
etiology while men have a 
one in nine chance.  
 
Women have been observed 
to have more tendencies 
towards diastolic heart 
failure as opposed to systolic 
heart failure. 
Douglas, P. & Poppas, A. 
(2012). Determinants and 
Management of 
Cardiovascular Risk in 
Women. UpToDate. 
Retrieved January 12, 2013 
from www.uptodate.com 
 
Literature review to 
identify the clinical 
presentation of heart 
disease and diagnostic 
testing considering gender 
differences. 
  Women with CHD are 
generally about 10 years 
older than men at the time of 
presentation which carries a 
greater burden of risk 
factors. 
 
Women are less likely than 
men to have typical angina 
(28% verses 55%) 
 
Silent myocardial infarctions 
were illustrated to be 
significantly higher in 
younger women than men 
(42% verses 30.7%). 
Incidence was noted to be 
higher in younger women 
then older women (41% 
verses 24%) 
 
A higher fraction of sudden 
deaths in women verses men 
occurred in the absence of 
prior CHD (63% verses 
44%) 
 
Many of the diagnostic 
testing statistics were 
considered by the authors to 
be less than accurate due to 
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the underrepresentation by 
women as well as the older 
age of then women who 
were included. 
Tamis-Holland, J., Lu, J., 
Bittner, V., Magee, M, Lopes, 
N., Adler, D., et al. (2011). 
Sex, Clinical Symptoms, and 
Angiographic Findings in 
Patients With Diabetes 
Mellitus and Coronary Artery 
Disease (from the Bypass 
Angioplasty 
Revascularization 
Investigation [BARI] 
2Diabetes Trial). American 
Journal of Cardiology, 107, 
980-985. 
 
This study was of 
observational design of the 
results concerning the 
BARI (2D) study. 
 
The purpose of this study 
was to determine the 
relationship between 
symptoms and extent of 
CAD in patients with type 
2 diabetes mellitus and 
known CAD enrolled in 
the Bypass Angioplasty 
Revascularization 
Investigation 2 Diabetes 
trial. 
2,368 patients from 
49 clinical sites were 
enrolled over a 
period of 50 months.  
 
Inclusion criteria 
was type 2 DM, 
documented CAD 
involving >1 
coronary vessel 
treatable and no 
previous 
cardiovascular 
treatment 
interventions or 
documented or 
known kidney 
disease. 
Baseline angiographies 
were assessed locally at 
clinical sites and sent to 
centralized core 
laboratory where it is 
analyzed for use in this 
study.  
 
Interpretation for 
inclusions in the study 
excluded 546 patients 
who were determined 
to not meet criteria. 
Of the remaining 1,775 
patients examined, 533 were 
women (representing 30% of 
total population inclusion). 
 
Women had less severe and 
significant CAD and less 
likely to have severe disease 
on coronary arteriogram as 
defined by multiple diseased 
LV regions (women vs men 
0.59, p <0.0001) 
 
Women vs men with 
significant occluded lesions 
on angiography 29% vs 
42%, p<0.001,  
 
Atypical symptomatic 
presentation: atypical angina 
71% vs 58% p<0.001, 
Nausea 24% vs 11% 
p<0.001 
Worrall-Carter, L., Ski, C., 
Scruth, E., Campbell, M. & 
Page, K. (2011). Systematic 
Review of Cardiovascular 
Disease in Women: Assessing 
the Risk. Nursing Health and 
Sciences, 13, 529.535. 
 
Systemic review using 
primary, secondary   
randomized and controlled 
studies 
 
The purpose of the review 
was to examine the 
cardiovascular disease risk 
in women to increase 
awareness of sex specific 
symptoms presentation, 
and risk factors to improve 
clinical outcomes. 
Women >18 years of 
age with at least one 
newly diagnosed or 
existing 
cardiovascular risk 
factor 
 INTERHEART study 
identified highest risk factors 
for myocardial infarction in 
women as diabetes mellitus 
and hypertension. It also 
identified 
hypertriglyceridemia as a 
known independent risk 
factor in women.  
 
Smoking was associated 
with a greater risk of AMI 
among women <45 years of 
age. The INTERHEART 
study concluded that 29% of 
AMI were a byproduct of 
smoking. 
 
DM was identified as having 
the greatest sex difference 
for developing CVD. 
Women with diabetes had a 
3-4 fold increased risk of 
developing CVD. 
 
Most CVD risks in women 
are modifiable. A study by 
the Nurses Health Study 
concluded that women were 
able to decrease their risk of 
developing CVD by 
eliminating their modifiable 
risk factors and maintaining 
a moderate healthy lifestyle. 
 
Women we 
underrepresented in CVD 
prevention and treatment 
trails or sex differences were 
not accounted for. The mean 
percentage of women 
enrolled in these trials was 
30% while only one-third of 
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trials reported results by 
gender. This leads to 
treatment recommendations 
tailored towards results from 
a predominantly male 
population. 
Matthew, K., Crawford, S., 
Chae, C., Everson-Rose, S., 
Sowers, M., Sternfield, B., et 
al. (2009) Are Changes in 
Cardiovascular Disease Risk 
Factors in Midlife Women 
Due to Chronological Aging 
or Menopausal Transition? 
Journal of the American 
College of Cardiology, 
54(25), 2366-2373. 
 
Longitudinal study over a 
timeframe of 10 years to 
examine whether changes 
in traditional and oval 
coronary heart disease risk 
factors are greater within a 
year of the final menstrual 
period, relative changes 
that occur before or after 
that interval, in a 
multiethnic cohort. 
1054 women who 
had their FMP by the 
end of 9 years of 
follow up in SWAN 
( a longitudinal 
multisite, 
community based 
study) 
The SWAN 
participants were 
questioned annually 
about health, lifestyle, 
and psychological 
factors. 
Anthropometric 
measurements and 
fasting blood draws 
were obtained at early 
follicular phase of the 
menstrual cycle at 
specific time intervals 
to allow a standardized 
hormonal milieu. 
 
The groups were 
divided into three time 
periods relative to FMP 
and the analytic sample 
was compared using 
chi-square and t tests. 
Increases in total cholesterol 
and LDL were substantial 
around time of FMP 
 
No difference was noted 
within ethnicity and these 
changes only in baseline 
weight measurements 
 
The analysis shows no 
influence of FMP on blood 
pressure, insulin, glucose or 
inflammatory factors 
Miller,V. & Best, P. (2009). 
Sex Differences in 
Cardiovascular Disease. 
Cardiovascular Disease, 9(3): 
21-28. 
 
Exploratory design intent 
on building groundwork of 
understanding the gender 
specific pathophysiology 
of cardiovascular disease 
in order to construct a risk 
assessment and treatment 
course tailored for women. 
 Effects of sex steroids 
on the factors 
contributing to 
cardiovascular disease 
were reviewed. 
 
Determine the 
participation rate in 
women in ongoing 
studies of CVD and 
how the representation 
of women are 
adequately or 
inadequate in current 
ongoing research. 
The proposed hypothesis 
shows validated assessment 
tool specific for women 
which incorporates 
information and history 
about pregnancy, 
reproductive history, and 
hormone exposure, might 
improve cardiovascular risk 
stratification for targeting 
early intervention in women 
as they age. 
 
CVD falls into 3 general 
categories with regard to sex 
disparity: 1) conditions 
unique to one sex, 2) 
conditions which occur in 
both sexes but have unique 
presentations in each sex, 3) 
those which have disparate 
prevalence rates yet occur in 
both genders. 
 
Sex steroids affect all 
components of the vascular 
wall, heart, as well as blood 
elements which come in 
contact with luminal 
surfaces. 
 
Finks, S. (2010). 
Cardiovascular Disease in 
Women. Cardiology, 7, 179-
199. 
 
The design of this study is 
of action research design.  
 
The purpose of this 
research was using both 
literature review, applying 
evidence based treatment 
guidelines and designing 
an optimal treatment 
options. 
 
  An estimated 66,000 more 
women than men die after 
acute myocardial infarction 
and intervention. Women 
also experience a higher 
mortality rate and poorer 
outcomes then men. 
 
Inflammatory markers 
indicating risk for CVD such 
as C-reactive protein 
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(hsCRP) are higher at 
baseline in women than men.  
 
Women with diabetes are 3-
7 times more at risk for 
developing or dying of CVD 
then women without 
diabetes. 
 
Premenopausal women have 
lower LDL and higher HDL 
levels then men whereas 
postmenopausal women 
experience elevated levels of 
LDL cholesterol and HDL 
levels continue to decline. 
 
A meta-analysis revealed a 
37% increased risk of CVD 
events in women with higher 
concentrations of 
triglycerides then that in 
men which showed a 14% 
increased risk. 
 
Hypertension in women is 
associated with a 2.5 higher 
risk of cardiovascular death, 
MI, stroke and heart failure 
in women compared to a 1.6 
increased risk in men with 
the same hypertension 
parameters. 
Mosca, L., Manson, J., 
Sutherland, S., Langer, R., 
Manolio, T., & Barrett-
Conner, E. (2009). 
Cardiovascular Disease in 
Women : A Statement for 
Healthcare Professionals 
From the American Heart 
Association. Circulation. 
Retrieved March 17, 2013 
from 
www.circ.ahajournals.org/con
tent/96/7/2468.full 
 
Cross-sectional design 
study conducted to 
determine the public 
awareness and knowledge 
of CVD as well as risk 
factor awareness as well as 
primary, secondary and 
tertiary prevention 
strategies. 
 Descriptive statistics of 
respondents 
characteristics, 
awareness, and 
preventative barriers 
were conducted to 
present the findings in 
relations to population 
proportions 
In evaluation of knowledge 
and awareness of leading 
cause of death among 
women, 55% correctly 
identified heart disease as 
the leading cause of death 
compared to 30% in 1997. 
 
81% answered they had 
read, seen, or heard 
information regarding heart 
disease in the past 12 
months. 
 
Tobacco use is attributed to 
50% of myocardial 
infarctions among middle 
aged women. 
 
Approximately half of all 
deaths in persons with non-
insulin dependent diabetes 
mellitus are due to heart 
disease. 
 
Hormone replacement 
therapy may indicate false 
ST depression. 
 
A meta analysis 
demonstrated a reduction of 
a second vascular event of 
25 % by using aspirin 
therapy. 
 
Lipid lowering therapy 
provides beneficial therapy 
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in women by decreasing 
hyperlipidemia and reducing 
mortality of women with 
CHD by >50%. 
 
Women were found to be 
less likely to enroll in 
rehabilitation then men 
(6.9% vs 13.3%) 
 
Women were less likely to 
undergo bypass surgery 
(20.4% vs 24.6%) then men. 
 
Incidence of stroke is higher 
in men (19%) then women, 
although women are more 
likely to die from a vascular 
occurrence (16% vs 8%). 
Walsh, J. & Pignone, M. 
(2004). Drug Treatment of 
Hyperlipidemia in Women. 
American Medical 
Association, 291,(18); 2243-
2252. 
 
Literature review including 
13 studies 
 
Studies that including 
gender differences, 
treatment duration of at 
least a year, 
 
6 trials included 
11435 women 
without CVD and 
using lipid lowering 
medications 
 
8 trials included 
8272 women with 
CVD and assessed 
the effects of lipid 
lowering 
medications 
MEDLINE database 
was used  
 
Inclusions were 1) 
randomized clinical 
trials of outpatients 
with or without CVD, 
2) treatment duration of 
at least a year, 3) 
classified the study as 
either primary ( without 
prior CVD) or 
secondary ( known 
CVD), 4) Provided data 
on women and the 
effect of lipid-lowing 
drug therapy 
Use of lipid-lowering 
medications in women 
without CVD, there was a 
possible reduction in CHD 
events (RR, 0.80; 95% CI, 
0.71 – 0.91) but not 
mortality. (RR, 0.95; 95%CI, 
0.62 – 1.46) 
 
In women with known CVD 
or at high risk, use of 
antihyperlipidemia 
medications showed a 
reduction in CHD events and 
CHD associated mortality. 
(RR 0.74;95% CI, 0.62-1.68) 
Xhyheri, B. & Bugiardini, R. 
(2010). Diagnosis and 
Treatment of Heart Disease; 
Are Women Different From 
Men? Progress in 
Cardiovascular Disease, 53, 
227-236. 
 
Literature review design 
which reviews current 
diagnostic and treatment 
options in reference to 
gender differences. 
  Aspirin therapy for CVD 
affects women differently 
than men. While it is more 
effective in preventing an 
MI in men (32%), it is more 
beneficial in preventing a 
stroke in women (17%). 
 
There is a lower level of 
preventative treatment of 
therapy in use of statins in 
women than men. 
 
Although the available 
literature concerning the use 
of ACE inhibitors in women 
in minimal, the research that 
is available shows a lower 
rate of effectiveness in 
women (22%)  then men 
(37%) concerning recovery 
from a MI and treatment for 
CHF. 
 
The benefit of the use 
concerning clopidogrel in 
treatment following a CVD 
event was lower in women 
(7%) then in men (16%) 
while the risk of bleeding 
from the use of clopidogrel 
was greater in women (43%) 
then in men (22%) 
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The benefits of B-blockers 
were shown in some trials to 
be more effective in women 
(31%) then in men (5%) 
 
Ahmed, W., Tully, P., Knight, 
J. & Baker, R. (2011). Female 
Sex as an Independent 
Predictor of Morbidity and 
Survival After Isolated 
Coronary Artery Bypass 
Grafting. The Annuls of 
Thoracic Surgery, 92(1); 59-
67. 
Case study design that 
sought to determine 
whether female sex was an 
independent risk factor for 
combined in-hospital 
morbidity, mortality, and 
long term survival after 
coronary artery bypass 
grafting (CABG). 
Data was collected 
for 1,114 women 
and 3,628 men who 
underwent coronary 
bypass grafting 
between January 1 
1996 and December 
31 2004 with a 
median follow up of 
7.9 years. 
Surgical coronary 
artery bypass grafting 
and in hospital 
rehabilitation 
The female sex was 
associated with being an 
increased risk factor in 
undergoing a CABG 
(adjusted odds ratio 1.29; 
95% CI, 1.04 to 1.59, p = 
0.02). Adjusted survival 
mode showed female sex 
was associated with cardiac 
mortality (hazard ratio 1.28; 
95% CI, 0.96 to 1.73; p = 
0.10) 
 
Females were older with 
lower body surface area and 
more significant comorbid 
conditions then did males 
(p<0.05) 
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